Thus, ctDNA-based signatures were better in predicting survival outcomes in advanced breast cancer treated with endocrine therapy and CDK4/6 inhibition than the same signatures when evaluated in tissue, suggesting that plasma-based signatures capture “the most up to date” biological state of the disease before starting therapy. Here, CDK4 is linked to breast carcinoma.